Serum calprotectin and joint ultrasound in the definition of disease relapse in non-systemic juvenile idiopathic arthritis: a prospective longitudinal study
Authors' conclusion
SC was able to identify JIA patients with unstable remission and increased risk of relapse. MSUS represents an interesting additional tool to the clinical evaluation, especially in predicting early relapse.
Study context
- Population
- Non-systemic juvenile idiopathic arthritis (JIA) patients in clinical remission
- Participants
- 60 patients
- Outcome
- Disease relapse; association of SC, US score and US ratio with relapse
- Follow-up
- Up to 18 months
Methodological detailslongitudinal, generalised estimating equations model
- Longitudinal
- Generalised estimating equations model
Main finding
As reported in the abstract
Predictors of relapse (overall odds up to 18 months)
Relapse within 18 months
31
51.6%
Higher baseline serum calprotectin (SC), overall odds of relapse, OR
1.21 (1.08-1.36) (95% CI)
Higher US scores, overall odds of relapse, OR
1.96 (1.56-2.46) (95% CI)
Higher US ratio, overall odds of relapse, OR
16.62 (7.17-38.54) (95% CI)
Observational data: associations, not effects.
Further findings
Relapse at 6 months by baseline US score
- Higher baseline US scores, OR
- 1.96 (1.09-3.52) (95% CI)
Relapse at 18 months by baseline SC
- Higher baseline SC, OR
- 1.66 (1.13-2.44) (95% CI)
Original publication
Serum calprotectin and joint ultrasound in the definition of disease relapse in non-systemic juvenile idiopathic arthritis: a prospective longitudinal study. Clin Exp Rheumatol. Published 28 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →